ethyl ((3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl)oxy)tetrahydro-2H-pyran-2-yl)methyl) carbonate (BioDeep_00000178860)
human metabolite blood metabolite
代谢物信息卡片
化学式: C26H38N2O9 (522.2577178)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 50%
分子结构信息
SMILES: CCOC(=O)OCC1C(C(C(C(O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
InChI: InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3
描述信息
同义名列表
5 个代谢物同义名
Ethyl (3,4,5-trihydroxy-6-{[5-methyl-1-(propan-2-yl)-4-{[4-(propan-2-yloxy)phenyl]methyl}-1H-pyrazol-3-yl]oxy}oxan-2-yl)methyl carbonic acid; Ethyl ((3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl)oxy)tetrahydro-2H-pyran-2-yl)methyl) carbonic acid; ethyl (3,4,5-trihydroxy-6-{[5-methyl-1-(propan-2-yl)-4-{[4-(propan-2-yloxy)phenyl]methyl}-1H-pyrazol-3-yl]oxy}oxan-2-yl)methyl carbonate; ethyl ((3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl)oxy)tetrahydro-2H-pyran-2-yl)methyl) carbonate; remogliflozin etabonate
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- James F Sigafoos, Gary D Bowers, Stephen Castellino, Amanda G Culp, David S Wagner, Melinda J Reese, Joan E Humphreys, Elizabeth K Hussey, Robin L O'Connor Semmes, Anita Kapur, Wenli Tao, Robert L Dobbins, Joseph W Polli. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Nov; 40(11):2090-101. doi:
10.1124/dmd.112.047258. [PMID: 22851617] - Sunder Mudaliar, Debra A Armstrong, Annie A Mavian, Robin O'Connor-Semmes, Patricia K Mydlow, June Ye, Elizabeth K Hussey, Derek J Nunez, Robert R Henry, Robert L Dobbins. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
Diabetes care.
2012 Nov; 35(11):2198-200. doi:
10.2337/dc12-0508. [PMID: 23011728] - R L Dobbins, R O'Connor-Semmes, A Kapur, C Kapitza, G Golor, I Mikoshiba, W Tao, E K Hussey. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
Diabetes, obesity & metabolism.
2012 Jan; 14(1):15-22. doi:
10.1111/j.1463-1326.2011.01462.x. [PMID: 21733056] - Asfandyar Khan Niazi, Saad Hameed Niazi. A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors.
North American journal of medical sciences.
2010 Dec; 2(12):556-60. doi:
10.4297/najms.2010.2556. [PMID: 22558567] - Yoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima, Yukiko Ishikawa-Takemura, Hideki Fujikura, Masayuki Isaji. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
The Journal of pharmacology and experimental therapeutics.
2008 Oct; 327(1):268-76. doi:
10.1124/jpet.108.140210. [PMID: 18583547]